nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—CYP3A4—bone cancer	0.287	1	CbGaD
Ezetimibe—UGT2B7—Epirubicin—bone cancer	0.0864	0.152	CbGbCtD
Ezetimibe—ABCC3—Cisplatin—bone cancer	0.0793	0.139	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—bone cancer	0.0532	0.0935	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—bone cancer	0.0515	0.0905	CbGbCtD
Ezetimibe—ABCC2—Carboplatin—bone cancer	0.0422	0.0742	CbGbCtD
Ezetimibe—ABCG2—Carboplatin—bone cancer	0.0381	0.0671	CbGbCtD
Ezetimibe—ABCC2—Cisplatin—bone cancer	0.036	0.0634	CbGbCtD
Ezetimibe—ABCG2—Cisplatin—bone cancer	0.0326	0.0573	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—bone cancer	0.0266	0.0468	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—bone cancer	0.0242	0.0425	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—bone cancer	0.0234	0.0412	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—bone cancer	0.0218	0.0384	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—bone cancer	0.0212	0.0372	CbGbCtD
Ezetimibe—ABCB1—Cisplatin—bone cancer	0.0118	0.0207	CbGbCtD
Ezetimibe—ABCB1—Doxorubicin—bone cancer	0.00788	0.0138	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—bone cancer	0.00763	0.0134	CbGbCtD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—T—bone cancer	0.00645	0.0744	CbGpPWpGaD
Ezetimibe—ABCG8—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00612	0.0707	CbGpPWpGaD
Ezetimibe—ABCG5—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00589	0.068	CbGpPWpGaD
Ezetimibe—CYP3A4—Doxorubicin—bone cancer	0.00472	0.0083	CbGbCtD
Ezetimibe—ABCG5—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00379	0.0438	CbGpPWpGaD
Ezetimibe—ABCG5—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00221	0.0256	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.00206	0.0238	CbGpPWpGaD
Ezetimibe—UGT2B15—Tamoxifen metabolism—CYP3A4—bone cancer	0.00191	0.022	CbGpPWpGaD
Ezetimibe—ABCC3—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00188	0.0217	CbGpPWpGaD
Ezetimibe—UGT2B7—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00188	0.0217	CbGpPWpGaD
Ezetimibe—ABCC3—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00176	0.0203	CbGpPWpGaD
Ezetimibe—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00153	0.0176	CbGpPWpGaD
Ezetimibe—ABCC2—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00149	0.0172	CbGpPWpGaD
Ezetimibe—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.0014	0.0161	CbGpPWpGaD
Ezetimibe—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00139	0.0161	CbGpPWpGaD
Ezetimibe—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00131	0.0151	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00121	0.014	CbGpPWpGaD
Ezetimibe—UGT1A3—Estrogen metabolism—CYP3A4—bone cancer	0.00115	0.0133	CbGpPWpGaD
Ezetimibe—ABCC3—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00103	0.0119	CbGpPWpGaD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00101	0.0117	CbGpPWpGaD
Ezetimibe—UGT2B7—Estrogen metabolism—CYP3A4—bone cancer	0.000982	0.0113	CbGpPWpGaD
Ezetimibe—UGT1A1—Irinotecan Pathway—CYP3A4—bone cancer	0.000975	0.0113	CbGpPWpGaD
Ezetimibe—ABCC2—Irinotecan Pathway—CYP3A4—bone cancer	0.000952	0.011	CbGpPWpGaD
Ezetimibe—UGT1A3—Metapathway biotransformation—CYP4V2—bone cancer	0.000946	0.0109	CbGpPWpGaD
Ezetimibe—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.000894	0.0103	CbGpPWpGaD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000875	0.0101	CbGpPWpGaD
Ezetimibe—UGT2B7—Tamoxifen metabolism—CYP3A4—bone cancer	0.000868	0.01	CbGpPWpGaD
Ezetimibe—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000828	0.00955	CbGpPWpGaD
Ezetimibe—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000815	0.0094	CbGpPWpGaD
Ezetimibe—UGT2B7—Metapathway biotransformation—CYP4V2—bone cancer	0.000805	0.00929	CbGpPWpGaD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000801	0.00924	CbGpPWpGaD
Ezetimibe—UGT1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000798	0.00921	CbGpPWpGaD
Ezetimibe—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000765	0.00883	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—MOGS—bone cancer	0.000743	0.00858	CbGpPWpGaD
Ezetimibe—UGT1A3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000729	0.00841	CbGpPWpGaD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—DHFR—bone cancer	0.000713	0.00823	CbGpPWpGaD
Ezetimibe—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.0007	0.00808	CbGpPWpGaD
Ezetimibe—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000656	0.00757	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000654	0.00755	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000654	0.00755	CbGpPWpGaD
Ezetimibe—ABCC3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00062	0.00715	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—KIT—bone cancer	0.000605	0.00699	CbGpPWpGaD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00059	0.00681	CbGpPWpGaD
Ezetimibe—UGT2B15—Phase II conjugation—GSTP1—bone cancer	0.000518	0.00598	CbGpPWpGaD
Ezetimibe—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000503	0.00581	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—NDUFA12—bone cancer	0.000497	0.00574	CbGpPWpGaD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000492	0.00568	CbGpPWpGaD
Ezetimibe—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000491	0.00567	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000482	0.00557	CbGpPWpGaD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000468	0.0054	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000464	0.00536	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—PTGS2—bone cancer	0.00046	0.00531	CbGpPWpGaD
Ezetimibe—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000429	0.00496	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000416	0.0048	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—NT5C3A—bone cancer	0.000412	0.00476	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—TUBB4B—bone cancer	0.000407	0.0047	CbGpPWpGaD
Ezetimibe—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000404	0.00466	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000401	0.00462	CbGpPWpGaD
Ezetimibe—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000383	0.00442	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—NDUFA12—bone cancer	0.000377	0.00435	CbGpPWpGaD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000377	0.00435	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—NDUFA12—bone cancer	0.000363	0.00419	CbGpPWpGaD
Ezetimibe—UGT2B15—Biological oxidations—CYP3A4—bone cancer	0.000354	0.00409	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—TUBB2A—bone cancer	0.000352	0.00406	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—NT5C3A—bone cancer	0.000312	0.00361	CbGpPWpGaD
Ezetimibe—UGT2B15—Biological oxidations—GSTP1—bone cancer	0.000303	0.0035	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—NT5C3A—bone cancer	0.000301	0.00347	CbGpPWpGaD
Ezetimibe—UGT1A3—Phase II conjugation—GSTP1—bone cancer	0.000277	0.0032	CbGpPWpGaD
Ezetimibe—Hepatic failure—Epirubicin—bone cancer	0.000264	0.00459	CcSEcCtD
Ezetimibe—Ill-defined disorder—Cisplatin—bone cancer	0.000258	0.00449	CcSEcCtD
Ezetimibe—Anaemia—Cisplatin—bone cancer	0.000257	0.00448	CcSEcCtD
Ezetimibe—Hot flush—Epirubicin—bone cancer	0.000253	0.00441	CcSEcCtD
Ezetimibe—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000252	0.00439	CcSEcCtD
Ezetimibe—Menopausal symptoms—Epirubicin—bone cancer	0.000251	0.00438	CcSEcCtD
Ezetimibe—Malaise—Cisplatin—bone cancer	0.000251	0.00437	CcSEcCtD
Ezetimibe—Photosensitivity—Doxorubicin—bone cancer	0.00025	0.00435	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—EIF2S1—bone cancer	0.000245	0.00283	CbGpPWpGaD
Ezetimibe—Hepatic failure—Doxorubicin—bone cancer	0.000244	0.00425	CcSEcCtD
Ezetimibe—Pain in extremity—Epirubicin—bone cancer	0.000237	0.00413	CcSEcCtD
Ezetimibe—Myalgia—Cisplatin—bone cancer	0.000237	0.00412	CcSEcCtD
Ezetimibe—UGT2B7—Phase II conjugation—GSTP1—bone cancer	0.000236	0.00272	CbGpPWpGaD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000235	0.00409	CcSEcCtD
Ezetimibe—Hot flush—Doxorubicin—bone cancer	0.000234	0.00408	CcSEcCtD
Ezetimibe—Liver function test abnormal—Methotrexate—bone cancer	0.000234	0.00407	CcSEcCtD
Ezetimibe—Discomfort—Cisplatin—bone cancer	0.000234	0.00407	CcSEcCtD
Ezetimibe—Menopausal symptoms—Doxorubicin—bone cancer	0.000232	0.00405	CcSEcCtD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000232	0.00268	CbGpPWpGaD
Ezetimibe—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000231	0.00267	CbGpPWpGaD
Ezetimibe—Breast disorder—Methotrexate—bone cancer	0.000229	0.00399	CcSEcCtD
Ezetimibe—Anaphylactic shock—Cisplatin—bone cancer	0.000227	0.00395	CcSEcCtD
Ezetimibe—Infection—Cisplatin—bone cancer	0.000225	0.00393	CcSEcCtD
Ezetimibe—Nervous system disorder—Cisplatin—bone cancer	0.000222	0.00388	CcSEcCtD
Ezetimibe—Thrombocytopenia—Cisplatin—bone cancer	0.000222	0.00387	CcSEcCtD
Ezetimibe—Skin disorder—Cisplatin—bone cancer	0.00022	0.00384	CcSEcCtD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00022	0.00254	CbGpPWpGaD
Ezetimibe—Pain in extremity—Doxorubicin—bone cancer	0.000219	0.00382	CcSEcCtD
Ezetimibe—Liver function test abnormal—Epirubicin—bone cancer	0.000219	0.00381	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000218	0.00251	CbGpPWpGaD
Ezetimibe—Eosinophilia—Methotrexate—bone cancer	0.000217	0.00378	CcSEcCtD
Ezetimibe—Pancreatitis—Methotrexate—bone cancer	0.000215	0.00374	CcSEcCtD
Ezetimibe—Breast disorder—Epirubicin—bone cancer	0.000214	0.00373	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000213	0.00372	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—NDUFA12—bone cancer	0.000212	0.00245	CbGpPWpGaD
Ezetimibe—Nasopharyngitis—Epirubicin—bone cancer	0.000212	0.00369	CcSEcCtD
Ezetimibe—Gastritis—Epirubicin—bone cancer	0.00021	0.00365	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000209	0.00364	CcSEcCtD
Ezetimibe—Muscular weakness—Epirubicin—bone cancer	0.000209	0.00364	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000207	0.0036	CcSEcCtD
Ezetimibe—Influenza—Epirubicin—bone cancer	0.000205	0.00357	CcSEcCtD
Ezetimibe—Paraesthesia—Cisplatin—bone cancer	0.000204	0.00355	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Methotrexate—bone cancer	0.000203	0.00354	CcSEcCtD
Ezetimibe—Eosinophilia—Epirubicin—bone cancer	0.000203	0.00353	CcSEcCtD
Ezetimibe—Liver function test abnormal—Doxorubicin—bone cancer	0.000202	0.00353	CcSEcCtD
Ezetimibe—Dyspnoea—Cisplatin—bone cancer	0.000202	0.00352	CcSEcCtD
Ezetimibe—Erectile dysfunction—Methotrexate—bone cancer	0.000202	0.00351	CcSEcCtD
Ezetimibe—Pancreatitis—Epirubicin—bone cancer	0.000201	0.0035	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Methotrexate—bone cancer	0.0002	0.00348	CcSEcCtD
Ezetimibe—Breast disorder—Doxorubicin—bone cancer	0.000198	0.00345	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000197	0.00344	CcSEcCtD
Ezetimibe—Decreased appetite—Cisplatin—bone cancer	0.000197	0.00344	CcSEcCtD
Ezetimibe—Nasopharyngitis—Doxorubicin—bone cancer	0.000196	0.00342	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Cisplatin—bone cancer	0.000196	0.00341	CcSEcCtD
Ezetimibe—Infestation—Methotrexate—bone cancer	0.000195	0.0034	CcSEcCtD
Ezetimibe—Infestation NOS—Methotrexate—bone cancer	0.000195	0.0034	CcSEcCtD
Ezetimibe—Gastritis—Doxorubicin—bone cancer	0.000194	0.00338	CcSEcCtD
Ezetimibe—Pain—Cisplatin—bone cancer	0.000194	0.00338	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—bone cancer	0.000193	0.00337	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000193	0.00337	CcSEcCtD
Ezetimibe—UGT1A1—Phase II conjugation—GSTP1—bone cancer	0.000192	0.00221	CbGpPWpGaD
Ezetimibe—Upper respiratory tract infection—Epirubicin—bone cancer	0.00019	0.00332	CcSEcCtD
Ezetimibe—UGT1A3—Biological oxidations—CYP3A4—bone cancer	0.00019	0.00219	CbGpPWpGaD
Ezetimibe—Influenza—Doxorubicin—bone cancer	0.00019	0.0033	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—bone cancer	0.000188	0.00327	CcSEcCtD
Ezetimibe—UGT1A3—Metapathway biotransformation—CYP3A4—bone cancer	0.000187	0.00216	CbGpPWpGaD
Ezetimibe—Photosensitivity reaction—Epirubicin—bone cancer	0.000187	0.00326	CcSEcCtD
Ezetimibe—Feeling abnormal—Cisplatin—bone cancer	0.000187	0.00326	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—bone cancer	0.000186	0.00324	CcSEcCtD
Ezetimibe—UGT1A3—NRF2 pathway—TGFBR2—bone cancer	0.000185	0.00214	CbGpPWpGaD
Ezetimibe—UGT1A3—NRF2 pathway—GSTP1—bone cancer	0.000185	0.00214	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000185	0.00213	CbGpPWpGaD
Ezetimibe—Hepatobiliary disease—Methotrexate—bone cancer	0.000185	0.00322	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—bone cancer	0.000183	0.00318	CcSEcCtD
Ezetimibe—Infestation NOS—Epirubicin—bone cancer	0.000183	0.00318	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—ENO2—bone cancer	0.000181	0.00208	CbGpPWpGaD
Ezetimibe—Body temperature increased—Cisplatin—bone cancer	0.000179	0.00312	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—bone cancer	0.000179	0.00312	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—bone cancer	0.000178	0.0031	CcSEcCtD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000177	0.00205	CbGpPWpGaD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000176	0.00307	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—NT5C3A—bone cancer	0.000176	0.00203	CbGpPWpGaD
Ezetimibe—Hepatitis—Methotrexate—bone cancer	0.000175	0.00305	CcSEcCtD
Ezetimibe—Pharyngitis—Methotrexate—bone cancer	0.000174	0.00303	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Doxorubicin—bone cancer	0.000173	0.00301	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—bone cancer	0.000173	0.00301	CcSEcCtD
Ezetimibe—Sinusitis—Epirubicin—bone cancer	0.000171	0.00299	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000171	0.00198	CbGpPWpGaD
Ezetimibe—Infestation—Doxorubicin—bone cancer	0.000169	0.00294	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—bone cancer	0.000169	0.00294	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—DHFR—bone cancer	0.000167	0.00193	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Cisplatin—bone cancer	0.000167	0.00291	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—bone cancer	0.000166	0.00289	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Doxorubicin—bone cancer	0.000166	0.00289	CcSEcCtD
Ezetimibe—Jaundice—Doxorubicin—bone cancer	0.000165	0.00287	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—bone cancer	0.000164	0.00286	CcSEcCtD
Ezetimibe—Asthenia—Cisplatin—bone cancer	0.000163	0.00284	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—bone cancer	0.000163	0.00284	CcSEcCtD
Ezetimibe—UGT1A3—Biological oxidations—GSTP1—bone cancer	0.000162	0.00187	CbGpPWpGaD
Ezetimibe—Oedema peripheral—Epirubicin—bone cancer	0.000162	0.00281	CcSEcCtD
Ezetimibe—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.000161	0.00186	CbGpPWpGaD
Ezetimibe—Connective tissue disorder—Epirubicin—bone cancer	0.000161	0.00281	CcSEcCtD
Ezetimibe—UGT1A3—Metapathway biotransformation—GSTP1—bone cancer	0.00016	0.00185	CbGpPWpGaD
Ezetimibe—Hepatobiliary disease—Doxorubicin—bone cancer	0.00016	0.00278	CcSEcCtD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	0.000159	0.00184	CbGpPWpGaD
Ezetimibe—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000159	0.00184	CbGpPWpGaD
Ezetimibe—Angiopathy—Methotrexate—bone cancer	0.000159	0.00277	CcSEcCtD
Ezetimibe—Sinusitis—Doxorubicin—bone cancer	0.000159	0.00276	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—bone cancer	0.000158	0.00276	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—bone cancer	0.000158	0.00275	CcSEcCtD
Ezetimibe—ABCC3—NRF2 pathway—GSTP1—bone cancer	0.000157	0.00182	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—TGFBR2—bone cancer	0.000157	0.00182	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000157	0.00182	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000157	0.00182	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—GNA11—bone cancer	0.000157	0.00181	CbGpPWpGaD
Ezetimibe—Diarrhoea—Cisplatin—bone cancer	0.000155	0.0027	CcSEcCtD
Ezetimibe—Erythema multiforme—Epirubicin—bone cancer	0.000155	0.0027	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—bone cancer	0.000155	0.0027	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—bone cancer	0.000153	0.00267	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—bone cancer	0.000153	0.00266	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—bone cancer	0.000153	0.00266	CcSEcCtD
Ezetimibe—Flushing—Epirubicin—bone cancer	0.000152	0.00265	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—bone cancer	0.000152	0.00264	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—bone cancer	0.000151	0.00262	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00015	0.00174	CbGpPWpGaD
Ezetimibe—Oedema peripheral—Doxorubicin—bone cancer	0.000149	0.0026	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—bone cancer	0.000149	0.0026	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—bone cancer	0.000149	0.00259	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—bone cancer	0.000148	0.00258	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—bone cancer	0.000148	0.00257	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—bone cancer	0.000148	0.00257	CcSEcCtD
Ezetimibe—Alopecia—Epirubicin—bone cancer	0.000145	0.00252	CcSEcCtD
Ezetimibe—Vomiting—Cisplatin—bone cancer	0.000144	0.00251	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—bone cancer	0.000144	0.0025	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—bone cancer	0.000143	0.0025	CcSEcCtD
Ezetimibe—Rash—Cisplatin—bone cancer	0.000143	0.00249	CcSEcCtD
Ezetimibe—Dermatitis—Cisplatin—bone cancer	0.000143	0.00249	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—bone cancer	0.000143	0.00249	CcSEcCtD
Ezetimibe—Erythema—Epirubicin—bone cancer	0.000143	0.00249	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—CYP3A4—bone cancer	0.000142	0.00164	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Methotrexate—bone cancer	0.000142	0.00247	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000141	0.00163	CbGpPWpGaD
Ezetimibe—Anaemia—Methotrexate—bone cancer	0.000141	0.00246	CcSEcCtD
Ezetimibe—Flushing—Doxorubicin—bone cancer	0.000141	0.00245	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—bone cancer	0.000141	0.00245	CcSEcCtD
Ezetimibe—Back pain—Epirubicin—bone cancer	0.000138	0.00241	CcSEcCtD
Ezetimibe—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000138	0.00159	CbGpPWpGaD
Ezetimibe—Angiopathy—Doxorubicin—bone cancer	0.000138	0.0024	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—bone cancer	0.000138	0.0024	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—bone cancer	0.000137	0.00239	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—bone cancer	0.000137	0.00239	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—ENO2—bone cancer	0.000137	0.00158	CbGpPWpGaD
Ezetimibe—Mediastinal disorder—Doxorubicin—bone cancer	0.000137	0.00238	CcSEcCtD
Ezetimibe—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000136	0.00157	CbGpPWpGaD
Ezetimibe—Nausea—Cisplatin—bone cancer	0.000135	0.00235	CcSEcCtD
Ezetimibe—Alopecia—Doxorubicin—bone cancer	0.000134	0.00234	CcSEcCtD
Ezetimibe—Cough—Methotrexate—bone cancer	0.000133	0.00232	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—bone cancer	0.000133	0.00232	CcSEcCtD
Ezetimibe—Ill-defined disorder—Epirubicin—bone cancer	0.000132	0.00231	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—bone cancer	0.000132	0.0023	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—bone cancer	0.000132	0.0023	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—bone cancer	0.000132	0.0023	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—ENO2—bone cancer	0.000132	0.00152	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.000131	0.00151	CbGpPWpGaD
Ezetimibe—Flatulence—Doxorubicin—bone cancer	0.00013	0.00227	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—bone cancer	0.00013	0.00226	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—bone cancer	0.00013	0.00226	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—bone cancer	0.00013	0.00226	CcSEcCtD
Ezetimibe—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000129	0.00149	CbGpPWpGaD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000129	0.00225	CcSEcCtD
Ezetimibe—Malaise—Epirubicin—bone cancer	0.000129	0.00224	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—bone cancer	0.000128	0.00224	CcSEcCtD
Ezetimibe—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.000128	0.00148	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.000128	0.00148	CbGpPWpGaD
Ezetimibe—Back pain—Doxorubicin—bone cancer	0.000128	0.00223	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—bone cancer	0.000127	0.00221	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—DHFR—bone cancer	0.000127	0.00147	CbGpPWpGaD
Ezetimibe—Palpitations—Epirubicin—bone cancer	0.000126	0.0022	CcSEcCtD
Ezetimibe—Confusional state—Methotrexate—bone cancer	0.000125	0.00219	CcSEcCtD
Ezetimibe—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000125	0.00144	CbGpPWpGaD
Ezetimibe—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000125	0.00144	CbGpPWpGaD
Ezetimibe—Cough—Epirubicin—bone cancer	0.000125	0.00217	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methotrexate—bone cancer	0.000124	0.00217	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000124	0.00143	CbGpPWpGaD
Ezetimibe—Infection—Methotrexate—bone cancer	0.000124	0.00215	CcSEcCtD
Ezetimibe—Hypertension—Epirubicin—bone cancer	0.000123	0.00215	CcSEcCtD
Ezetimibe—Ill-defined disorder—Doxorubicin—bone cancer	0.000123	0.00213	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—DHFR—bone cancer	0.000122	0.00141	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Methotrexate—bone cancer	0.000122	0.00213	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—bone cancer	0.000122	0.00213	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—bone cancer	0.000122	0.00212	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—bone cancer	0.000122	0.00212	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—bone cancer	0.000122	0.00212	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—bone cancer	0.000122	0.00212	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—GSTP1—bone cancer	0.000121	0.0014	CbGpPWpGaD
Ezetimibe—Skin disorder—Methotrexate—bone cancer	0.000121	0.00211	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000121	0.0021	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—bone cancer	0.00012	0.00209	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—bone cancer	0.000119	0.00208	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—bone cancer	0.000119	0.00207	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—GNA11—bone cancer	0.000119	0.00137	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000118	0.00137	CbGpPWpGaD
Ezetimibe—Confusional state—Epirubicin—bone cancer	0.000117	0.00205	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—bone cancer	0.000117	0.00203	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—bone cancer	0.000116	0.00203	CcSEcCtD
Ezetimibe—Infection—Epirubicin—bone cancer	0.000116	0.00202	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—bone cancer	0.000115	0.00201	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—bone cancer	0.000114	0.00199	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—GNA11—bone cancer	0.000114	0.00132	CbGpPWpGaD
Ezetimibe—Thrombocytopenia—Epirubicin—bone cancer	0.000114	0.00199	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—bone cancer	0.000114	0.00199	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000114	0.00131	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000113	0.00198	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—bone cancer	0.000113	0.00197	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—bone cancer	0.000113	0.00196	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—bone cancer	0.000112	0.00196	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—bone cancer	0.000112	0.00196	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—bone cancer	0.000112	0.00196	CcSEcCtD
Ezetimibe—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000112	0.00129	CbGpPWpGaD
Ezetimibe—Paraesthesia—Methotrexate—bone cancer	0.000112	0.00195	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000112	0.00195	CcSEcCtD
Ezetimibe—Discomfort—Doxorubicin—bone cancer	0.000111	0.00194	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—bone cancer	0.000111	0.00193	CcSEcCtD
Ezetimibe—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000111	0.00128	CbGpPWpGaD
Ezetimibe—Dry mouth—Doxorubicin—bone cancer	0.00011	0.00192	CcSEcCtD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.00011	0.00127	CbGpPWpGaD
Ezetimibe—Dyspepsia—Methotrexate—bone cancer	0.00011	0.00191	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—bone cancer	0.000109	0.00189	CcSEcCtD
Ezetimibe—Decreased appetite—Methotrexate—bone cancer	0.000108	0.00189	CcSEcCtD
Ezetimibe—Anaphylactic shock—Doxorubicin—bone cancer	0.000108	0.00188	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—CYP3A4—bone cancer	0.000108	0.00124	CbGpPWpGaD
Ezetimibe—Gastrointestinal disorder—Methotrexate—bone cancer	0.000107	0.00187	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—bone cancer	0.000107	0.00187	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—bone cancer	0.000107	0.00187	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000107	0.00124	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000107	0.00123	CbGpPWpGaD
Ezetimibe—Pain—Methotrexate—bone cancer	0.000106	0.00185	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000106	0.00185	CcSEcCtD
Ezetimibe—Nervous system disorder—Doxorubicin—bone cancer	0.000106	0.00184	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—bone cancer	0.000106	0.00184	CcSEcCtD
Ezetimibe—Insomnia—Epirubicin—bone cancer	0.000105	0.00184	CcSEcCtD
Ezetimibe—Skin disorder—Doxorubicin—bone cancer	0.000105	0.00182	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—bone cancer	0.000105	0.00182	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—bone cancer	0.000104	0.00181	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—CYP3A4—bone cancer	0.000104	0.0012	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000103	0.00119	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Methotrexate—bone cancer	0.000103	0.00179	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—bone cancer	0.000103	0.00179	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—bone cancer	0.000102	0.00177	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—bone cancer	0.000101	0.00176	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—bone cancer	0.000101	0.00175	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—bone cancer	0.0001	0.00175	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—MMP2—bone cancer	0.0001	0.00116	CbGpPWpGaD
Ezetimibe—Constipation—Epirubicin—bone cancer	9.96e-05	0.00174	CcSEcCtD
Ezetimibe—Pain—Epirubicin—bone cancer	9.96e-05	0.00174	CcSEcCtD
Ezetimibe—Urticaria—Methotrexate—bone cancer	9.89e-05	0.00172	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—bone cancer	9.84e-05	0.00171	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—bone cancer	9.84e-05	0.00171	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.82e-05	0.00171	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.81e-05	0.00113	CbGpPWpGaD
Ezetimibe—Insomnia—Doxorubicin—bone cancer	9.75e-05	0.0017	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—bone cancer	9.68e-05	0.00169	CcSEcCtD
Ezetimibe—ABCC3—Metabolism—NDUFA12—bone cancer	9.67e-05	0.00112	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NDUFA12—bone cancer	9.67e-05	0.00112	CbGpPWpGaD
Ezetimibe—Dyspnoea—Doxorubicin—bone cancer	9.61e-05	0.00167	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—bone cancer	9.6e-05	0.00167	CcSEcCtD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	9.58e-05	0.00111	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	9.56e-05	0.0011	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Epirubicin—bone cancer	9.52e-05	0.00166	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—bone cancer	9.49e-05	0.00165	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—NT5C3A—bone cancer	9.42e-05	0.00109	CbGpPWpGaD
Ezetimibe—Decreased appetite—Doxorubicin—bone cancer	9.37e-05	0.00163	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—bone cancer	9.3e-05	0.00162	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—bone cancer	9.29e-05	0.00162	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—bone cancer	9.25e-05	0.00161	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—bone cancer	9.22e-05	0.00161	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—bone cancer	9.22e-05	0.00161	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.21e-05	0.00106	CbGpPWpGaD
Ezetimibe—Body temperature increased—Epirubicin—bone cancer	9.21e-05	0.0016	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—bone cancer	9.21e-05	0.0016	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—GSTP1—bone cancer	9.2e-05	0.00106	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Methotrexate—bone cancer	9.17e-05	0.0016	CcSEcCtD
Ezetimibe—Asthenia—Methotrexate—bone cancer	8.93e-05	0.00156	CcSEcCtD
Ezetimibe—Feeling abnormal—Doxorubicin—bone cancer	8.88e-05	0.00155	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—GSTP1—bone cancer	8.85e-05	0.00102	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Doxorubicin—bone cancer	8.81e-05	0.00154	CcSEcCtD
Ezetimibe—Pruritus—Methotrexate—bone cancer	8.81e-05	0.00153	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—bone cancer	8.58e-05	0.0015	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—bone cancer	8.56e-05	0.00149	CcSEcCtD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.53e-05	0.000984	CbGpPWpGaD
Ezetimibe—Abdominal pain—Doxorubicin—bone cancer	8.52e-05	0.00148	CcSEcCtD
Ezetimibe—Body temperature increased—Doxorubicin—bone cancer	8.52e-05	0.00148	CcSEcCtD
Ezetimibe—Diarrhoea—Methotrexate—bone cancer	8.52e-05	0.00148	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.47e-05	0.000977	CbGpPWpGaD
Ezetimibe—Asthenia—Epirubicin—bone cancer	8.36e-05	0.00146	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—bone cancer	8.24e-05	0.00144	CcSEcCtD
Ezetimibe—Dizziness—Methotrexate—bone cancer	8.23e-05	0.00143	CcSEcCtD
Ezetimibe—ABCC3—Metabolism—NT5C3A—bone cancer	8.01e-05	0.000925	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NT5C3A—bone cancer	8.01e-05	0.000925	CbGpPWpGaD
Ezetimibe—Diarrhoea—Epirubicin—bone cancer	7.97e-05	0.00139	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.95e-05	0.000918	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Doxorubicin—bone cancer	7.94e-05	0.00138	CcSEcCtD
Ezetimibe—Vomiting—Methotrexate—bone cancer	7.91e-05	0.00138	CcSEcCtD
Ezetimibe—UGT1A1—Metabolism—NDUFA12—bone cancer	7.86e-05	0.000907	CbGpPWpGaD
Ezetimibe—Rash—Methotrexate—bone cancer	7.85e-05	0.00137	CcSEcCtD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.84e-05	0.000905	CbGpPWpGaD
Ezetimibe—Dermatitis—Methotrexate—bone cancer	7.84e-05	0.00137	CcSEcCtD
Ezetimibe—Headache—Methotrexate—bone cancer	7.8e-05	0.00136	CcSEcCtD
Ezetimibe—Asthenia—Doxorubicin—bone cancer	7.73e-05	0.00135	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—ENO2—bone cancer	7.71e-05	0.00089	CbGpPWpGaD
Ezetimibe—Dizziness—Epirubicin—bone cancer	7.7e-05	0.00134	CcSEcCtD
Ezetimibe—Pruritus—Doxorubicin—bone cancer	7.63e-05	0.00133	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—bone cancer	7.41e-05	0.00129	CcSEcCtD
Ezetimibe—Nausea—Methotrexate—bone cancer	7.39e-05	0.00129	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—bone cancer	7.37e-05	0.00128	CcSEcCtD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.36e-05	0.00085	CbGpPWpGaD
Ezetimibe—Rash—Epirubicin—bone cancer	7.34e-05	0.00128	CcSEcCtD
Ezetimibe—Dermatitis—Epirubicin—bone cancer	7.34e-05	0.00128	CcSEcCtD
Ezetimibe—Headache—Epirubicin—bone cancer	7.3e-05	0.00127	CcSEcCtD
Ezetimibe—SLCO1B1—Metabolism—NDUFA12—bone cancer	7.2e-05	0.000831	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—DHFR—bone cancer	7.15e-05	0.000825	CbGpPWpGaD
Ezetimibe—Dizziness—Doxorubicin—bone cancer	7.13e-05	0.00124	CcSEcCtD
Ezetimibe—Nausea—Epirubicin—bone cancer	6.92e-05	0.00121	CcSEcCtD
Ezetimibe—Vomiting—Doxorubicin—bone cancer	6.85e-05	0.00119	CcSEcCtD
Ezetimibe—Rash—Doxorubicin—bone cancer	6.8e-05	0.00118	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—bone cancer	6.79e-05	0.00118	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—bone cancer	6.75e-05	0.00118	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—GNA11—bone cancer	6.68e-05	0.000771	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.67e-05	0.00077	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NDUFA12—bone cancer	6.67e-05	0.00077	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—NT5C3A—bone cancer	6.51e-05	0.000752	CbGpPWpGaD
Ezetimibe—Nausea—Doxorubicin—bone cancer	6.4e-05	0.00112	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—PTGS2—bone cancer	6.29e-05	0.000726	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.07e-05	0.000701	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CYP3A4—bone cancer	6.06e-05	0.000699	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NT5C3A—bone cancer	5.97e-05	0.000689	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.53e-05	0.000638	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NT5C3A—bone cancer	5.53e-05	0.000638	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.46e-05	0.00063	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—GSTP1—bone cancer	5.18e-05	0.000598	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.17e-05	0.000597	CbGpPWpGaD
Ezetimibe—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.89e-05	0.000565	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTGS2—bone cancer	4.77e-05	0.00055	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.62e-05	0.000534	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.61e-05	0.000532	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTGS2—bone cancer	4.59e-05	0.000529	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ENO2—bone cancer	4.13e-05	0.000476	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.98e-05	0.000459	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—DHFR—bone cancer	3.83e-05	0.000442	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NDUFA12—bone cancer	3.61e-05	0.000416	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GNA11—bone cancer	3.58e-05	0.000413	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ENO2—bone cancer	3.51e-05	0.000405	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ENO2—bone cancer	3.51e-05	0.000405	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.43e-05	0.000396	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—DHFR—bone cancer	3.26e-05	0.000376	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—DHFR—bone cancer	3.26e-05	0.000376	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CYP3A4—bone cancer	3.25e-05	0.000375	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.17e-05	0.000366	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.13e-05	0.000361	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GNA11—bone cancer	3.04e-05	0.000351	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GNA11—bone cancer	3.04e-05	0.000351	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NT5C3A—bone cancer	2.99e-05	0.000345	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ENO2—bone cancer	2.85e-05	0.000329	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTP1—bone cancer	2.78e-05	0.00032	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP3A4—bone cancer	2.76e-05	0.000318	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP3A4—bone cancer	2.76e-05	0.000318	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.75e-05	0.000317	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTGS2—bone cancer	2.68e-05	0.00031	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—DHFR—bone cancer	2.65e-05	0.000305	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ENO2—bone cancer	2.61e-05	0.000302	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.54e-05	0.000293	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GNA11—bone cancer	2.47e-05	0.000285	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.45e-05	0.000283	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—DHFR—bone cancer	2.42e-05	0.00028	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ENO2—bone cancer	2.42e-05	0.000279	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTP1—bone cancer	2.36e-05	0.000272	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTP1—bone cancer	2.36e-05	0.000272	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GNA11—bone cancer	2.27e-05	0.000262	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—DHFR—bone cancer	2.25e-05	0.000259	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP3A4—bone cancer	2.24e-05	0.000259	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NDUFA12—bone cancer	2.22e-05	0.000256	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.21e-05	0.000255	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GNA11—bone cancer	2.1e-05	0.000242	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.05e-05	0.000237	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.04e-05	0.000236	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTP1—bone cancer	1.92e-05	0.000221	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP3A4—bone cancer	1.9e-05	0.00022	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NT5C3A—bone cancer	1.84e-05	0.000212	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTP1—bone cancer	1.76e-05	0.000203	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.74e-05	0.000201	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTP1—bone cancer	1.63e-05	0.000188	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.46e-05	0.000168	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTGS2—bone cancer	1.44e-05	0.000166	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ENO2—bone cancer	1.31e-05	0.000151	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTGS2—bone cancer	1.22e-05	0.000141	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTGS2—bone cancer	1.22e-05	0.000141	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—DHFR—bone cancer	1.21e-05	0.00014	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GNA11—bone cancer	1.13e-05	0.000131	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP3A4—bone cancer	1.03e-05	0.000119	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTGS2—bone cancer	9.93e-06	0.000115	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTGS2—bone cancer	9.1e-06	0.000105	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTP1—bone cancer	8.8e-06	0.000102	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTGS2—bone cancer	8.43e-06	9.73e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ENO2—bone cancer	8.06e-06	9.31e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—DHFR—bone cancer	7.48e-06	8.63e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GNA11—bone cancer	6.99e-06	8.07e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTP1—bone cancer	5.42e-06	6.26e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTGS2—bone cancer	4.56e-06	5.26e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTGS2—bone cancer	2.81e-06	3.24e-05	CbGpPWpGaD
